QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

Help viewing high resolution images Return to article

Fig. 7. Actomyosin contractility is not sufficient to activate SRF. (A) Effect of Blebbistatin and Y-27632 on induction of SRF by Ca²⁺ withdrawal. MDCK cells were transfected and treated as before. Blebbistatin (100 µM, 2.5 hours pretreatment) and Y-27632 (20 µM, 30 minutes pretreatment) was added prior to medium exchange and maintained throughout the assay. (B) Rac1 and RhoA activity following Blebbistatin pretreatment. Pull-down assays were performed as in Fig. 5 for Rac1 or RhoA, either 5 or 2 minutes after medium exchange, respectively. (C) Blebbistatin effect on the actin cytoskeleton. Confluent monolayers were pretreated for 2.5 hours with Blebbistatin prior to medium exchange for 7 hours, as in A. Cells were fixed and stained for E-cadherin and F-actin (phalloidin). Shown are micrographs from cells maintained in normal (left) or low (right) Ca²⁺. (D) No effect of constitutively active ROCK4 or the myosin-phosphatase inhibitor calyculin A on SRF activity. Calyculin A was added 30 minutes before medium exchange and maintained throughout the assay. (E) Influences of ROCK4 and calyculin A on the actin cytoskeleton. Cells were transfected or treated as before and stained for myc (ROCK4) and F-actin (phalloidin). Mock, medium exchange with 1.8 mM Ca²⁺; –Ca²⁺, medium exchange with 0.02 mM Ca²⁺; CalA, treated with calyculin A (5 nM). Error bars indicate s.e.m. (n=3). Bars, 50 µm.

Return to article